A detailed analysis of T-cell redirecting therapies in oncology, comparing the mechanisms of bispecific antibodies and CAR T ...
Emerging pathways can help cell and gene therapies become commercially viable for intractable diseases, even with uneven scalability and consistency.
Technology Adoption Program (TAP) program success demonstrates the ability of Cellares’ IDMO Smart Factory to automate, lower costs and scale out manufacturing for Cabaletta Bio’s clinical-stage CAR T ...
A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s Cellares has passed another major production milestone. Cellares’ automated ...
The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...
Cell and gene therapy (CGT) has evolved from a niche research pursuit into a central force in biopharmaceutical innovation. By engineering living cells and genetic material to repair or replace faulty ...
Cellares, in collaboration with Mitsui Fudosan, a Japanese real estate developer, established Japan’s first next-gen commercial production site for CAR-T cell therapies. The facility is under ...
Collaboration with Stanford Medicine establishes a platform manufacturing process and analytics designed to support gene-edited hematopoietic stem cell therapies for HIV and more than 19 rare diseases ...
Stevenage, UK, and Boca Raton, Florida, US, April 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) a clinical-stage biotechnology company targeting inflammation and immunology through the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results